T
The420Guy
Guest
GW Pharmaceuticals plc enhances cannabinoid research activities, appoints
Professor Roger Pertwee as Director of Pharmacology
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked
cannabis-based prescription medicines, announces that Professor Roger
Pertwee, Professor of Neuropharmacology at the University of Aberdeen, has
joined GW's senior management team as Director of Pharmacology at GW.
Professor Pertwee is one of the world's leading cannabinoid scientists,
having researched this area for over 30 years, and is the author of over
220 publications. He is a Past President of the International Cannabinoid
Research Society and is frequently consulted about the therapeutic
potential of cannabis and cannabinoids by parliamentary committees as well
as leading medical organisations.
In his role at GW, Professor Pertwee will focus on pharmacology in support
of the company's clinical trials programmes and novel research, including
the investigation of new therapeutic areas.
The appointment marks the first step in the planned establishment by GW of
a new research entity - the Cannabinoid Research Institute. The Institute
will be a distinct division within the company and its activities will be
directed by Dr Philip Robson, GW's Medical Director. The Institute will
allow GW to expand its operations from clinical and pre-clinical work into
fundamental cannabinoid research.
Professor Pertwee said, "The prospect of exploring the pharmacological
actions of individual plant cannabinoids, separately and in combination, is
exciting for both scientific and clinical reasons. The setting up of the
Institute will greatly facilitate fundamental research into the
pharmacology of plant cannabinoids and the exploitation of these
constituents of cannabis as medicines."
"Bringing together a pharmaceutical company and academic scientists with a
common interest in cannabinoid pharmacology in this way will be a highly
effective combination, consisting as it will of three powerful elements:
adequate funding, appropriate expertise and research that is focussed and
of high-quality".
Dr Robson commented, "This is a most exciting time for GW. We welcome
Professor Pertwee and look forward to working with him. We hope over time
to involve other collaborators, so that scientists from inside and outside
GW can conduct research into the mammalian cannabinoid system and potential
therapeutic candidates for cannabis-based medicines."
Dr Geoffrey Guy, Executive Chairman of GW, commented, "It is our aim that
GW should occupy the centre ground of cannabinoid science. We are therefore
building a bridge between commercial enterprise and academia by
establishing the Cannabinoid Research Institute. We are confident that this
is the best way for GW to undertake fundamental science, and to investigate
the future commercial opportunities which may arise with phytocannabinoids,
which occur in plants, as well as synthetic cannabinoids and also
endocannabinoids, which occur naturally within the human body."
Professor Roger Pertwee as Director of Pharmacology
GW Pharmaceuticals plc, the company developing a portfolio of non-smoked
cannabis-based prescription medicines, announces that Professor Roger
Pertwee, Professor of Neuropharmacology at the University of Aberdeen, has
joined GW's senior management team as Director of Pharmacology at GW.
Professor Pertwee is one of the world's leading cannabinoid scientists,
having researched this area for over 30 years, and is the author of over
220 publications. He is a Past President of the International Cannabinoid
Research Society and is frequently consulted about the therapeutic
potential of cannabis and cannabinoids by parliamentary committees as well
as leading medical organisations.
In his role at GW, Professor Pertwee will focus on pharmacology in support
of the company's clinical trials programmes and novel research, including
the investigation of new therapeutic areas.
The appointment marks the first step in the planned establishment by GW of
a new research entity - the Cannabinoid Research Institute. The Institute
will be a distinct division within the company and its activities will be
directed by Dr Philip Robson, GW's Medical Director. The Institute will
allow GW to expand its operations from clinical and pre-clinical work into
fundamental cannabinoid research.
Professor Pertwee said, "The prospect of exploring the pharmacological
actions of individual plant cannabinoids, separately and in combination, is
exciting for both scientific and clinical reasons. The setting up of the
Institute will greatly facilitate fundamental research into the
pharmacology of plant cannabinoids and the exploitation of these
constituents of cannabis as medicines."
"Bringing together a pharmaceutical company and academic scientists with a
common interest in cannabinoid pharmacology in this way will be a highly
effective combination, consisting as it will of three powerful elements:
adequate funding, appropriate expertise and research that is focussed and
of high-quality".
Dr Robson commented, "This is a most exciting time for GW. We welcome
Professor Pertwee and look forward to working with him. We hope over time
to involve other collaborators, so that scientists from inside and outside
GW can conduct research into the mammalian cannabinoid system and potential
therapeutic candidates for cannabis-based medicines."
Dr Geoffrey Guy, Executive Chairman of GW, commented, "It is our aim that
GW should occupy the centre ground of cannabinoid science. We are therefore
building a bridge between commercial enterprise and academia by
establishing the Cannabinoid Research Institute. We are confident that this
is the best way for GW to undertake fundamental science, and to investigate
the future commercial opportunities which may arise with phytocannabinoids,
which occur in plants, as well as synthetic cannabinoids and also
endocannabinoids, which occur naturally within the human body."
